Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
ChiCTR2600125501 Ticagrelor Cerebrovascular Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
ChiCTR2600125501 clinical trial report covering Ticagrelor, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07564726 Amlodipine Besylate Primary hypercholesterolemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07564726 clinical trial report covering Amlodipine Besylate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07593924 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(Sinovac Life Sciences) Pneumococcal Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07593924 clinical trial report covering 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(Sinovac Life Sciences), Phase 3, endpoints, sponsor, geo
Latest Hotspot
8 min read
NCT07563634 Brivaracetam Epilepsies, Partial Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07563634 clinical trial report covering Brivaracetam, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
8 min read
CRLF1 Biologics Sequence Review Report 2026: Cytokine receptor-like factor 1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CRLF1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
C1QTNF9B Biologics Sequence Review Report 2026: Complement C1q and tumor necrosis factor-related protein 9B Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of C1QTNF9B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CR1L Biologics Sequence Review Report 2026: Complement component receptor 1-like protein Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CR1L protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
C1QTNF7 Biologics Sequence Review Report 2026: Complement C1q tumor necrosis factor-related protein 7 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of C1QTNF7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
C1QTNF9 Biologics Sequence Review Report 2026: Complement C1q and tumor necrosis factor-related protein 9A Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of C1QTNF9 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
C1QTNF6 Biologics Sequence Review Report 2026: Complement C1q tumor necrosis factor-related protein 6 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of C1QTNF6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
C1QTNF8 Biologics Sequence Review Report 2026: Complement C1q tumor necrosis factor-related protein 8 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of C1QTNF8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
C1QTNF4 Biologics Sequence Review Report 2026: Complement C1q tumor necrosis factor-related protein 4 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of C1QTNF4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.